Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks nice heading into next week
Looks like show time...
GL
Set to join the russell microcap index!!!
With these kind of results I think Delcath should start pursuing sale to a bigger device or oncology company soon. Going alone would be foolish, a bigger device or oncology company can easily make this standard of care, would be harder for a small company to do the same.
I like the idea of a $600 market cap goal, either 2021 or 2022. I would factor in 15 million shares outstanding, but $40 works for me, I have a good position I hope to sell none before $18
Today's new data is striking, 44% vs 17% improvement for best overall response not just Delcath vs placebo, but Delcath vs "best alternative care". Not many FDA approved treatments can boast such improvements over best alternate care, many are approved based on improvements over placebo.
as you know well, co was once $600 million...
Filterthenoise can be discounted I am sad to say...
"filter"(out) filter is right! :)
Creeping... Should get fun in the coming weeks
Nice close today. Might be about to turn the corner in the immediate weeks ahead
That is why I am happy to be away from the years when I shot for homeruns, preservation of capital works for me as I have managed funds and individual stocks of around 20 to 25
Given Phase 3 was OK, so far as we know now, stock price is weird... low.
delcath is not unique, but for all practical purpose should be seen as at least 15 million shares fully diluted but loads of cash at that point. I would think $600 million market cap with that factored in is a fair assessment. I am a little worried about the finish up of phase 3, but risk is more than factored in
There are probably just a couple hundred shareholders worldwide in DCTH, rest of the investment community will probably only find out after next Friday. A 60 million market cap is a joke, has 10X potential.
Oral presentation at the very prestigious ASCO conference coming up next Friday, so ten days to go! The ASCO abstract is below, the presentation is for 12 minutes to a potentially large medical audience, so this is a big deal.
"144 patients were enrolled overall; 102 were assigned to PHP (301: n=43; 301A: n=59) and 42 were assigned to BAC. 91 PHP patients received treatment (301: n=40; 301A: n=51) and 32 BAC patients received treatment. At the time of this analysis, 4 PHP patients were still ongoing on study treatment with a minimum follow-up of 24 weeks. 79 PHP-treated patients and 29 BAC-treated patients were evaluable for response. ORR among PHP patients was 32.9% (26/79; 95% CI: 22.75-40.40%). ORR among BAC patients was 13.8% (4/29; 95% CI: 3.89-31.66%). The median PFS was 9.03 months (95% CI: 6.24-11.83) among PHP patients and was 3.06 months (95% CI: 2.69-5.65) among BAC patients; this difference was statistically significant (p=0.0004). Among the 94 patients assessed for safety after treatment with PHP, 40.4% of patients experienced a serious treatment-emergent adverse event, the majority of which were hematological and resolved without sequelae. There were no treatment related deaths in the trial."
Can anyone comment on when full data release will be. I read mid year but also heard ceo say on a call end of year.
Thanks
DCTH SHOULD be rising!!!
They have a podium presentation at ASCO.
We are buying.
I don't know how these virtual meetings are going but in the old days ASCO was the golden ticket for companies that had P2 or P3 presentations. Lots of visibility to both the scientific community, doctors, pharma and investment community. Let's see how this year plays out and how the ASCO attendees process the data, would also be interesting to see who and how many attend their presentation.
Webinar is june 7 8:30 am et. To discuss....Positive preliminary re-
sults from its PHASE 3 FOCUS trial of HEPZATO in patients with metestatic ocular melanoma. The full meeting program is avail. @ www.asco.org
and again...
Best of luck.
We bought now again.
Doubt they want to lose money... Grabbed some 10s too. Hopefully we turn around here
She is coiled
GL
DCTH just filed a Statement of changes in beneficial ownership of securities
Inbox
info@conferencecalltranscripts.org via server.conferencecalltranscripts.com
8:09 AM (55 minutes ago)
to me
Greetings neal.hurwitz@gmail.com,
Delcath Systems (DCTH) just filed a Statement of changes in beneficial ownership of securities.
Don't want to see ads? Become a site Patron
Learn more about RevenueStripe...
A summary of the filing is available below:
Delcath Systems's Chief Operating Officer just picked up 4,000 shares
John Purpura, Delcath Systems's Chief Operating Officer, recently acquired 4,000 shares of the company. The buys took place at $9.42 per share, on May 13, 2021. Purpura now owns 18,713 shares of the company. Purpura operates out of New York, NY. Some additional info was provided as follows:
The above information was disclosed in a filing to the SEC. To see the filing, click here.
You are receiving this message because you signed up at http://www.conferencecalltranscripts.org to receive this notification. To stop receiving these notifications, please go to http://www.conferencecalltranscripts.org/portfolio/ to manage your notifications.
Great buy pre-ASCO at these levels. Final data will be presented at ASCO to the medical community where the attention is big. Expect this to be back to mid 20s or even higher after the ASCO data presentation.
I'm looking to add more on signs of a reversal here. Waiting for a break and hold of $12 is safer option
Stocks do these things and this pullback isn't just DCTH specific.
Just have to wait out the games and take some at the deep discount
I am not a stock technical guru, but it does not look appealing to the uneducated tech. The risk/reward though is outstanding, this is priced in for 6 month delay easy and if no delay, voila
Greater markets forces had to do their thing over the last 3 months. Its not just DCTH by any means.
Shake the weak, tire-out the impatient & not so subtly load up the shares before the larger move. The volume at $12-13 tells you all you need to know about interest/demand & gives some comfort to be patient. Volume very often precedes price.
I'm just a chart guy but I firmly believe the future is much brighter then you know. Much, much brighter. Anyone who been around here for years deserves all that is coming in the upcoming months as we start to see serious growth
GL
Hope you are right, of course.
I have been with this for manyyyy years.
We'll look back on this time as a serious gift one day
Looking forward to the fire
GL
I don't think p3 release was botched. I do want final results this year. Down the line at least 15 million shares outstanding. Based on history 500 million market cap can be challenged. So I see $25 as quite possible at some point. Maybe double of 25. Best case would include a decision to start a trial on colorectal related liver, if it is talked up convincingly. Then more than $1 billion market cap but this message board would likely be on fire
Short term, yes. Chart is set-up for nicely short and long term. I got eyes for much higher.
This drop to $11 area was a gift and now all coiled up from over the last 3 months.
$100M worth of shares accumulated in one day at the end of March
Wont be long now
GL
Msg 57488 of 57488 at 5/6/2021 4:13:35 PM by
basketwatcher
report abuse
Strong Buy
ASCO will be the catalyst
The ASCO presentation of P3 results is to the scientific community and can fix the problems that happened in the botched release of preliminary data in Feb. The data looks very good for approval and DCTH could easily have gone to a 200 million valuation on it but slipped. I think there are funds who will see value and take positions prior to the ASCO presentation. Looking at 20s again in summer after ASCO.
All small numbers in the bigger picture.
Well be up to $100 on the next leg I bet.
GL
11.34... up from 9 where I bought most... down from 25...
Corrective wave almost done...
It was also loaded heavily around $12. This is gravy down here, wont stay this way much longer
It'll turn north sharply in the coming days.
This is the biggest position I have had in delcath since 2012. The downside would be if this phase 3 fell apart, otherwise little risk until middle of next year when FDA weighs in
11.9... might be good buy here now...
Followers
|
496
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
50154
|
Created
|
05/11/05
|
Type
|
Free
|
Moderators |
In December 2018, Delcath entered into a License Agreement with medac GmbH for the commercialization of the CHEMOSAT® system in Europe. Under the terms of the medac License, medac has the exclusive right to sell and market CHEMOSAT® in all member states of the EU, Norway, Liechtenstein, Switzerland, and the United Kingdom.
Since launching CHEMOSAT® in Europe, over 750 commercial treatments have been performed at over 25 European cancer centers. Physicians in Europe have used CHEMOSAT® to treat patients with a variety of cancers in the liver, primarily ocular melanoma liver metastases, and other tumor types including cutaneous melanoma, hepatocellular carcinoma, cholangiocarcinoma, and liver metastases from colorectal cancer, breast, pancreatic and neuroendocrine.Split # | Date | Ratio |
1 | April 9, 2014 | 1:16 |
2 | July 21, 2016 | 1:16 |
3 | November 6, 2017 | 1:350 |
4 | May 2, 2018 | 1:500 |
5 | December 24, 2019 | 1:700 |
Common Shares Authorized: | 1,000,000,000 |
Common Shares Outstanding: | 70,056 |
Preferred Shares Authorized: | 10,000,000 |
Preferred Shares Outstanding: | 41,447 |
Warrants: | 29 | ($42; exp 2/2020 - 10/2021) |
2019 Warrants: | 1,826,579 | ($23.04; exp 12/2024) |
Options: | 1,640 | |
Total Warrants/Options: | 1,828,248 |
Preferred Stock: | 1,799,093 |
Convertible Notes: | 63,493 |
Total Reserved: | 1,862,586 |
Jennifer K. Simpson, Ph.D. | : 2,965 |
John Purpura, M.S. | : 2,830 |
William D. Rueckert | : 2,619 |
Roger G. Stoll, Ph.D. | : 4,047 |
Marco Taglietti, M.D. | : 2,606 |
Total Shares | : 21,459 |
Altium Capital Management L.P. | : 7,204 |
Rosalind Master Fund L.P. | : 7,024 |
Hudson Bay Master Fund Ltd. | : 7,024 |
Total Shares | : 21,612 |
45 Shareholders (est.) | : 26,985 |
Company Website: Delcath Systems, Inc. | Stock and Financial Website: OTC Marketplace |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |